GlassScriptPhysician profile
Lesley Ann Stead
NPI 1811174592
$3,700.58
in general payments reported to CMS, 2019-2025
20 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $174 · 2021: $43.45 · 2022: $296 · 2023: $19.18 · 2024: $359 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $997 · Food and Beverage: $634 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $997.00 |
| Food and Beverage | $634.26 |
| Education | $210.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,165.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $652.17 | 2019-2025 | Eliquis, Opdivo, Camzyos |
| Astellas Pharma US INC | $347.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $298.24 | 2019-2025 | Tagrisso, Enhertu |
| Lilly USA, LLC | $243.66 | 2022-2025 | Verzenio |
| Janssen Biotech, INC. | $171.21 | 2019-2024 | Darzalex |
| Genentech USA, INC. | $150.99 | 2019 | |
| Celgene Corporation | $124.42 | 2019 | |
| Pfizer INC. | $110.73 | 2019 | |
| Merck Sharp & Dohme LLC | $105.14 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Clovis Oncology, INC. | $104.91 | 2019 | |
| Glaxosmithkline, LLC. | $48.30 | 2019-2025 | Ojjaara |
| Incyte Corporation | $28.65 | 2025 | Monjuvi, Zynyz |
| Exelixis INC. | $26.87 | 2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $26.76 | 2025 | Xpovio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $26.15 | 2025 | Mi Cancer Seek |
| Acrotech Biopharma INC. | $24.74 | 2025 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2020 | |
| Amgen INC. | $14.25 | 2022 | |
| Kyowa Kirin, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Stead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.